SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISON OF GLASDEGIB PLUS LOW DOSE ARA-C VERSUS A HYPOMETHYLATING AGENT FOR ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY

被引：0
|
作者：
Forsythe, A. [1 ]
Arondekar, B. [2 ]
Tremblay, G. [1 ]
Chan, G. [2 ]
Su, Y. [3 ]
机构：
[1] Purple Squirrel Econ, New York, NY USA
[2] Pfizer Inc, Collegeville, PA USA
[3] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.103
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN21
引用
收藏
页码：A415 / A415
页数：1
相关论文
共 50 条
  • [41] Dose escalation of ara-C may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-α and low-dose ara-C
    Hilbe, W
    Kühr, T
    Apfelbeck, U
    Fridrik, M
    Seewann, H
    Stöger, M
    Linkesch, W
    Pont, J
    Baldinger, C
    Hartner, E
    Bernhart, M
    Geissler, D
    Krieger, O
    Lang, A
    Lin, W
    Ludwig, H
    Duba, C
    Greil, R
    Gastl, G
    Thaler, J
    LEUKEMIA & LYMPHOMA, 2001, 42 (06) : 1283 - 1288
  • [42] Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review
    Cortes, Jorge E.
    Candoni, Anna
    Clark, Richard E.
    Leber, Brian
    Montesinos, Pau
    Vyas, Paresh
    Zeidan, Amer M.
    Heuser, Michael
    LEUKEMIA & LYMPHOMA, 2020, 61 (14) : 3287 - 3305
  • [43] Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation
    Elsayed, Abdelrahman H.
    Cao, Xueyuan
    Mitra, Amit K.
    Wu, Huiyun
    Raimondi, Susana
    Cogle, Christopher
    Al-Mansour, Zeina
    Ribeiro, Raul C.
    Gamis, Alan
    Kolb, Edward Anders
    Aplenc, Richard
    Alonzo, Todd A.
    Meshinchi, Soheil
    Rubnitz, Jeffrey
    Pounds, Stanley
    Lamba, Jatinder K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (07) : 772 - 783
  • [44] Comparison of the cyclophosphailiide (C), ara-c (A), topotecan (T), (CAT) regimen to ara-c plus topotecan or idarubicin (I) as initial therapy for patients with adverse abnormal karyotype acute myeloid leukemia (AML).
    Beran, H
    Giles, FJ
    Cortes, JE
    Thomas, DA
    Koller, C
    O'Brien, SM
    Keating, MJ
    Freireich, E
    Kantarjian, HM
    Estey, E
    BLOOD, 1999, 94 (10) : 226B - 226B
  • [45] A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
    Berdel, Andrew F.
    Koch, Raphael
    Gerss, Joachim
    Hentrich, Marcus
    Peceny, Rudolf
    Bartscht, Tobias
    Steffen, Bjoern
    Bischoff, Marina
    Spiekermann, Karsten
    Angenendt, Linus
    Mikesch, Jan-Henrik
    Kewitz, Tobias
    Butterfass-Bahloul, Trude
    Serve, Hubert
    Lenz, Georg
    Berdel, Wolfgang E.
    Krug, Utz
    Schliemann, Christoph
    ANNALS OF HEMATOLOGY, 2023, 102 (01) : 63 - 72
  • [46] A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
    Andrew F. Berdel
    Raphael Koch
    Joachim Gerss
    Marcus Hentrich
    Rudolf Peceny
    Tobias Bartscht
    Björn Steffen
    Marina Bischoff
    Karsten Spiekermann
    Linus Angenendt
    Jan-Henrik Mikesch
    Tobias Kewitz
    Trude Butterfass-Bahloul
    Hubert Serve
    Georg Lenz
    Wolfgang E. Berdel
    Utz Krug
    Christoph Schliemann
    Annals of Hematology, 2023, 102 : 63 - 72
  • [47] High dose ARA-C as consolidation therapy for patients with core binding factor acute myeloid leukemia.
    Ferrara, F
    Copia, C
    Palmieri, S
    Annunziata, M
    Pollio, F
    Mele, G
    Schiavone, EM
    BLOOD, 2000, 96 (11) : 326A - 326A
  • [48] Autophagy induction of Acute Myeloid Leukemia (AML) cells after treatment with low dose-cytarabine (Ara-C) and enhanced cytocidal effect on AML cells by combined treatment with ara-c plus lenograstim
    Tang, Yongmin
    Li, Lixia
    Wang, Di
    Shen, Hongqiang
    Qian, Baiqin
    Luo, Chunfang
    Zhang, Haizhong
    BLOOD, 2007, 110 (11) : 114B - 114B
  • [49] Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia
    Matthews, Andrew H.
    Perl, Alexander E.
    Luger, Selina M.
    Gill, Saar I.
    Lai, Catherine
    Porter, David L.
    Skuli, Sarah
    Bruno, Ximena Jordan
    Carroll, Martin P.
    Freyer, Craig W.
    Carulli, Alison
    Babushok, Daria V.
    Frey, Noelle V.
    Hexner, Elizabeth O.
    Martin, Mary Ellen
    McCurdy, Shannon R.
    Stadtmauer, Edward A.
    Loren, Alison W.
    Paralkar, Vikram R.
    Maillard, Ivan P.
    Pratz, Keith W.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (08) : 1254 - 1264
  • [50] Clofarabine and clofarabine plus low-dose cytarabine (ara-C) as induction therapy for patients (pts) ≥ 60 years with newly diagnosed acute myeloid leukemia (AML)
    Faderl, S
    Ravandi, F
    Ferrajoli, A
    Garcia-Manero, G
    Estrov, Z
    Thomas, DA
    O'Brien, S
    Verstovsek, S
    Wierda, W
    Cortes, J
    Giles, FJ
    Kwari, M
    Jarmon, R
    Kantarjian, HM
    BLOOD, 2005, 106 (11) : 786A - 786A
12345